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Neutrophils are the most abundant leukocytes in peripheral blood and respond rapidly to danger, inﬁltrating tissues within minutes
of infectious or sterile injury. Neutrophils were long thought of as simple killers, but now we recognise them as responsive cells able
to adapt to inﬂammation and orchestrate subsequent events with some sophistication. Here, we discuss how these rapid responders
release mediators which inﬂuence later adaptive T cell immunity through inﬂuences on DC priming and directly on the T cells
themselves. We consider how the release of granule contents by neutrophils—through NETosis or degranulation—is one way in
which the innate immune system directs the phenotype of the adaptive immune response.1. Neutrophils Are Sophisticated Cells Able to
Adapt to Changing Inflammation
Neutrophils are not simple bags of enzymes sent to kill path-
ogens before the adaptive immune cells move in. In fact, they
are able to respond to altered inﬂammatory status; neutro-
phils can produce cytokines [1], alter their gene expression
during inﬂammation [2] and throughout “aging” [3], and
survive for signiﬁcantly longer than traditionally thought,
with one study placing lifespan from bonemarrow at 5.4 days
[4]. As a consequence, neutrophils are able to adapt to chang-
ing conditions and direct other cells’ behaviour—a task
which they can perform with some sophistication.2. The Adaptive T Cell Response Generates in
the Presence of Neutrophil Mediators
As adaptive immune responses develop, T cells are primed by
dendritic cells (DCs) in the lymph node and proliferate in situ
before moving into the tissue where their antigen of interest is
situated. Here, they encounter antigen, receive additional sig-
nals fromantigen-presenting cells (APCs) and local cytokines,
and carry out their eﬀector functions. However, this response
does not happen in isolation. TheDCs scanning for antigen in
the respiratory tract during inﬂuenza infection, for example,also encountermillions of neutrophils, which can out number
themmanyfold [5, 6], as do the inﬂuenza-speciﬁcT cellswhich
subsequentlyleavethelymphnodeatthepeakofinﬂammation.
As these neutrophils will be degranulating, dying, and produc-
ing extracellular traps (NETs, [7]), the DC and T cells are in
eﬀect moving into a soup of neutrophil-produced inﬂamma-
tory mediators. It is no surprise that these mediators have
profound eﬀects on T cell diﬀerentiation, survival, prolifera-
tion, and eﬀector function.
In this review, we will consider how the granule contents
released during neutrophil degranulation and NETosis aﬀect
the development of adaptive T cell responses. We are discuss-
ing extrudedmediators only, andnot the antigen-presentation
capacities or cell-cell interactions performed by neutrophils
nor the outcomes of whole apoptotic or necrotic neutrophils
being engulfed. It is our contention that the inﬂammatory
mediators released by neutrophils allow these innate cells to
exert somecontrol over the tissue environment anddirect later
adaptive immune responses.3. Conflicting Data onHowNeutrophils Affect T
Cell Responses
Recent years have seen an explosion of research into how
neutrophils aﬀect DC and T cell biology; however, these data
2 Mediators of Inﬂammationare confusing, with neutrophils either suppressing or pro-
moting T cell activation depending on the context (Figure 1).
There are a number of murine models in which the T cell
responses can be exacerbated by depleting neutrophils,
implying they have a regulatory role [8, 9]. This suppression
of T cell responses by neutrophils requires close contact and
development of an immunological synapse [10, 11]—perhaps
as the mediators thought responsible, reactive oxygen species
and H2O2 do not diﬀuse far. Uptake of apoptotic or necrotic
neutrophils also inhibits DC antigen presentation and co-
stimulation, resulting in reduced T cell responses—a situation
which can be exploited by pathogens. For example, neutro-
phils capture L. major and are subsequently engulfed by DCs,
suppressing antigen presentation and T cell priming [12, 13].
In the second group of research, neutrophils are proin-
ﬂammatory andpromoteT cell responses.Neutrophils induce
the migration, maturation, proinﬂammatory cytokine
production, and priming capabilities of DCs through contact-
and cytokine/chemokine-dependent mechanisms [14–23].
Depletion of neutrophils in mouse models of inﬂammatory
disease leads to decreases in virus-speciﬁc CD8+ T cell
responses [24] and a lack of skewing to protective subsets
[25, 26]. Further, neutrophils can directly present antigen to
T cells and directly stimulate T cell proliferation in response
to superantigen [27–31].
It is not yet clear why and how these two situations exist. It
mayreﬂect thepresenceofdiﬀerentpopulationsofneutrophils
[32] which are not yet stratiﬁed; for example, the maturation
status of neutrophils released from the bone marrow during
sepsis, which are suppressive to T cells [10], diﬀers markedly
from those present in the highly inﬂammatory environment
of hyperlipidemia [33], which are primed and produce high
levels of myeloperoxidase. In addition, the ability of neutro-
phils to alter their expression of surface molecules and to
transcribe RNA once they have left the bone marrow means
the generation of localised populations of cells may well have
diﬀerential eﬀects on adaptive immunity (reviewed in [34]).
Other possibilities are that the diﬀerent eﬀects noted are
a consequence of the inﬂammatory model or infection used
or of particular features of dendritic cell or T cell biology
that are only expressed in certain inﬂammatory states; the
situation may also reﬂect diﬀerent experimental techniques,
particularly for the isolation of neutrophils (see Section 5 - a
note on immature and low density neutrophils). Further,
murine and human neutrophils do diﬀer in many ways
(reviewed in [35]) and use of mouse models must be consid-
ered as a variable.
In this review, we attempt to discuss a number of ways in
which neutrophil granule contents aﬀect priming, diﬀerentia-
tion, and survival of αβ T cells. These granule peptides also
show a variety of eﬀects, with both suppressive and activatory
impacts on T cell immunity—we discuss the complexity of
these responses.
4. Impact of Neutrophil Granule Contents of
DC-T Cell Immunity
4.1. Degranulation. Degranulation is the exocytosis of anti-
microbial or cytotoxic molecules from intracellular granules,which functions as a defence mechanism to kill invading
microbes. Neutrophils are activated and undergo degranula-
tion through a variety of ligands (including LPS, IL-8, fMLF,
and C5a) binding to cell-surface receptors which include G
protein-coupled receptors (GPCR), Fc-receptors (Fc-R),
pattern recognition receptors (PRRs), and chemokine
receptors [36–38].
Following neutrophil activation, diﬀerent granules pos-
sess distinct propensities for extracellular release. Neutrophil
granules are divided into diﬀerent subsets—primary (azuro-
philic), secondary (secretory), and tertiary (gelatinase)
granules in addition to secretory vesicles (SVs). The diﬀerent
granules are formed sequentially during neutrophil diﬀeren-
tiation and are released in the opposite order; the timing of
synthesis determines the sequence in which the granules are
released [39–42]. The strict hierarchy of release is secre-
tory vesicles then tertiary, secondary, and ﬁnally primary
granules [37].
Proteomic analysis delineating granule contents [43, 44]
reveals that primary granules contain myeloperoxidase
(MPO), serine proteases cathepsin G and neutrophil elastase
(NE), and alpha defensins; secondary granules contain anti-
microbial proteins and peptides including lactoferrin and
cathelicidin (hCAP-18), pentraxin and haptoglobin, and
some metalloproteinases (MMPs); ﬁnally, tertiary granules
contain gelatinase, lysozyme, and some MMPs.
In this section, we discuss the contribution of components
of these granules toT cell immunity. Table 1 lists a summary of
results for prominent mediators from each granule.
4.1.1. Myeloperoxidase. MPO is a 150 kDa cationic dimeric
protein which produces hypochlorous acid from H2O2 and
chloride during the respiratory burst; it is present in the
primary granules and is an important antimicrobial agent
[45, 46].
MPO-speciﬁc CD4+ T cells are present in patients with
anti-MPO glomerulonephritis (GN) [47–49]; these canmedi-
ate glomerular injury directly as they recognise MPO released
from neutrophils undergoing degranulation, apoptosis, and
NETosis, inducing [50] delayed-typehypersensitivity through
enhanced IFN-γ production. Immunising mice with MPO in
this model leads to increased inﬁltration of CD4+ T cells
[48]. Likewise, direct injection of MPO during a model of
anti-MPO glomerulonephritis induced signiﬁcant IL-17A
production and development of an MPO-speciﬁc DTH
response as well as renal disease [51]. Therefore, in this partic-
ular inﬂammatory disease, MPO induces strongly proinﬂam-
matory T cell responses owing to it being an autoantigen.
However, in other forms of glomerulonephritis where
MPO is not an autoantigen (including antiglomerular base-
ment membrane GN and pristine-induced lupus nephritis),
endogenous MPO suppresses T cell responses. Here,
MPO-/- mice showed increased CD4+ T cell accumulation
and proliferation suggesting MPO attenuates T cell responses
[52, 53]. MPO has profoundly suppressive eﬀects on DC and
CD4+ T cells in vitro and in vivo. MPO inhibits
ConA-induced proliferation of human T cells in vitro [54],
and CD4+ T cells have increased activation, proliferation,
and proinﬂammatory cytokine production in MPO-/- mice
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Figure 1: Neutrophils impact T cell immunity through many methods. Neutrophils undergo cell-cell contact, NETosis, degranulation, and
cytokine release which aﬀects T cell responses by either activating or suppressing their function. (1) Primary granules, (2) secondary granules,
and (3) tertiary granules.
3Mediators of Inﬂammation[55]. This was mediated by neutrophils depositing MPO in
lymph nodes, where it decreases DC migration and
activation. In agreement with this, mice lacking MPO have
enhanced T cell immunity and more severe antigen-induced
arthritis [55].
In addition, the reactive intermediate taurine chloramine,
formed as a result of MPO-catalyzed reactions, inhibits the
release of TNF-α, IL-6, and IL-12 from murine DC and
inhibits the capacity of DC to induce the release of IL-2 and
IL-10 from T cells in vitro therefore suppressing T cell
activity [56, 57].
It is important to note that the majority of work demon-
strating a proinﬂammatory T cell response to MPO has been
performed in patients with anti-MPO glomerulonephritis
and vasculitis, who present with ANCA (antineutrophil
cytoplasmic antibodies) which react to proteinase 3 and
MPO in particular; this disease may involve unusual mecha-
nisms of action of MPO not found in healthy individuals
including it acting as an autoantigen.
4.1.2. Alpha Defensins. The human neutrophil peptides
(HNP1-3), also known as α-defensins, are small (c.4 kDa),
cationic, amphipathic antimicrobial peptides which are
highly abundant in neutrophils, comprising 30-50% of the
protein content of primary granules; they are not present in
mouse neutrophils (entertainingly reviewed in [58]).
Firstly, α-defensins can induce migration of adaptive
immune cells. HNP1 chemoattracts T cells [59–61] and
immature DC, although data is conﬂicting on this point, with
one report showing an increase in migration of naïve CD4+ Tcells only [61] and another showing memory cell migration
was also increased [60]. Stimulation of lung epithelial cells
with HNP leads to increased adhesion of CD4+ T cells [62]
and production of IFN-γ, IL-2, and IL-8. Adhesion is
promoted by increased expression of CD28 and LFA1 on
the T cells enabling increased binding to epithelial CD80,
CD86, and ICAM1.
Once they are in close proximity, HNP1 can induce pDC
to produce IFN-α [63] via degradation of I-κBα and nuclear
translocation of IRF1. Similar signalling is seen in CD4+ T
cells; HNP induces translocation of NF-κB p50 to the nucleus
and induced degradation of I-kB [62]. HNP1 also promotes
an increase in the costimulatory molecules CD80, CD86,
and CD40 on human monocyte-derived DC [64] as well as
maturation markers. In a mixed lymphocyte reaction, DC
treated with HNP1 increased T cell proliferation.
Interestingly, there are concentration-dependent out-
comes following the exposure of human monocyte-derived
DC to α-defensins [65]. Low-medium doses of HNP1-3 (up
to 1μg/ml) led to a slight increase in CD86 and HLA-DR
expression, while higher doses inhibited the expression of
these molecules. Likewise, low dose increased DC production
of IL-1β, TNF, IL-12p40, and IL-10, while higher doses
inhibited this strongly. Consequently, low dose of HNP1-3
increased the DC stimulation of T cell proliferation, and high
dose reduced this.
4.1.3. Neutrophil Elastase. Neutrophil elastase (ELANE, NE)
is a potent serine protease with broad speciﬁcity stored in
the primary azurophil granules alongside MPO and
Table 1: Abundant contents of neutrophil granules and their impact on T cell immunity.
Mediator Granule Eﬀect on DC/T cells Outcome Species Reference
MPO Primary
Is a T cell antigen Activatory
Human,
mouse
[47, 48]
Induces IL-17A production, due to being an autoantigen Activatory Mouse [51]
Suppresses lymphocyte proliferation Suppressive Human [54]
Suppresses CD4+ T cell responses Suppressive Mouse [55]
Suppresses DC activation and cytokine production Suppressive
Mouse,
human
[53, 55]
MPO-/- mice have enhanced T cell responses in arthritis Suppressive Mouse [55]
MPO-/- mice have increased T cell responses in nephritis Suppressive Mouse [52, 53]
HNPs
Primary (only
human)
Low dose: matures, activates, and induces cytokine secretion
by DC
Activatory Human [65]
Chemoattracts naïve but not memory T cells Activatory Human [61]
Chemoattracts naïve and memory T cells Activatory Human [60]
Are produced by monocyte-derived DC Activatory Human [118]
HNP1 induces pDC to produce IFNα Activatory Human [63]
Enhances T cell adhesion to lung epithelium Activatory Human [62]
Induces NF-κB signalling in CD4+ T cells Activatory Human [62]
HNPs are anti-inﬂammatory to DC Suppressive Human [169]
High dose: inhibits activation, induces IL-8 Suppressive Human [65]
Elastase Primary
Is a T cell antigen Activatory Human [71]
Strongly promotes Th17 responses via cleavage of DC CXCL8 Activatory Human [72]
Induces DC to prime Treg Suppressive Human [69]
Induces DC to produce TGF-β Suppressive Human [68]
Suppresses T cell proliferation in an MLR Suppressive Human [68]
Reduces T cell transmigration Suppressive Human [66]
Inhibits DC maturation and suppresses costimulation Suppressive Human [70]
LL-37 Secondary
Is a T cell antigen Activatory Human [73]
Induces proliferation CD4+ T cells (+ PHA) Activatory Human [74]
Is a chemoattractant for CD4+ T cells (FPR2 dependent) Activatory
Human,
mouse
[61, 77,
78]
Activates CD8+ T cells and induces degranulation Activatory Mouse [75]
Matures DC primes Th1 responses Activatory Human [80]
Complexes DNA and is taken up by pDC Activatory Human [82, 84]
Enhances vaccination against tumour model Activatory House [85]
Induces DC CD86 and migration to CCR7 ligands Activatory Mouse [81]
Boosts T cell proliferation and cytokine production at
immunisations
Activatory Mouse [78]
Is internalised into cytoplasm and nucleus of DC, inducing
CD86
Activatory Human [170]
Induces apoptosis Treg Activatory Mouse [90]
Induces apoptosis CD8+ T cells Suppressive Mouse [89]
Prevents development Th2 in vitro Suppressive Mouse [91]
Suppresses IFN-γ activation of DC Suppressive Human [86]
Inhibits DC responses to TLR4 ligands Suppressive Mouse [87]
Inhibits TLR signalling to DC Suppressive Human [88]
Lactoferrin Secondary
Is taken up by T cells Pig [107]
Matures and activates DC Activatory Human
[92, 94,
96]
Promotes T cell proliferation and Th1 generation Activatory Human
4 Mediators of Inﬂammation
Table 1: Continued.
Mediator Granule Eﬀect on DC/T cells Outcome Species Reference
[92, 94,
96]
Increases inﬂammation during DTH response Activatory Mouse [95]
Boosts CD4+ IFN-γ production in concert with BCG
vaccination
Activatory Mouse [97]
Upregulates the CD4 molecule Activatory Human [100]
Increases T cell cytokine production during infection Activatory Mouse [101]
Increases intestinal CD8+ T cell activation Activatory Mouse [108]
Decreases proinﬂammatory CD4+ cells in intestinal
inﬂammation
Suppressive Mouse [111]
Prevents T cell proliferation in an MLR Suppressive Human [113]
Prevents Th1 but not Th2 proliferation Suppressive Human [114]
Arginase-1 Tertiary
Suppresses T cell proliferation via TCR-zeta Suppressive
Human,
mouse
[115, 117]
Induces cell cycle arrest Suppressive Human [118]
Inhibits development of immunological synapse Suppressive Human [120]
Gelatinase Tertiary Induces DC migration and T cell priming in DTH Activatory Mouse [125]
MPO: myeloperoxidase; DC: dendritic cell; HNP: human neutrophil peptide; pDC: plasmacytoid dendritic cell; IFN-α: interferon-α; NF-κβ: nuclear
factor-kappa beta; MLR: mixed lymphocyte reaction; PHA: phytohemagglutinin; FPR2: formylpeptide receptor 2; IFNγ: interferon-gamma; TLR: toll-like
receptor; DTH: delayed-type hypersensitivity.
5Mediators of Inﬂammationα-defensins. However, unlike the others, elastase shows
mostly anti-inﬂammatory and regulatory roles (aside from
its bacterial-killing capabilities).
Neutrophils transmigrating to sites of inﬂammation
secrete elastase [66] which suppresses later SDF-1—induced
T cell transmigration (but not subsequent neutrophil migra-
tion). This suppression was found to be elastase dependent.
In macrophages, elastase cleaves TLR2, TLR4, and MD-2
[67], suppressing proinﬂammatory cytokine production and
impairing host defence in a pneumonia model. We do not yet
know whether a similar phenomenon occurs with DC, but
elastase does induce human immature DC—but not fully
mature cells—to shut oﬀ IL-6 production and increase
TGF-β [68, 69]. In a mixed lymphocyte reaction, DC treated
with elastase showed a twofold increase in regulatory T cell
generation compared to control-treated cells [69] and an
overall suppression of lymphocyte proliferation [68]. What
is interesting in this study was that DCs treated with primed
neutrophil supernatant—that collected following IL-8
priming and albumin-induced degranulation—also induced
an increase in Treg in a TGF-β-dependent fashion. Likewise,
elastase—and, more generally, supernatant from sputum iso-
lated from patients with chronic obstructive pulmonary dis-
ease and Cystic Fibrosis—suppressed the DC expression of
costimulatory markers, the latter in an elastase-dependent
manner [70]. It remains to be explained how elastase can sup-
press DC responses and induce regulatory T cells, when in
these contexts—sputum, or whole neutrophil supernatant—it
is present alongside so many proinﬂammatory mediators.
However, two pieces of work do suggest a proinﬂamma-
tory role for elastase. IFN-γ producing T cells speciﬁc for
neutrophil elastase have been identiﬁed [71]. These T cells
were shown to be present in 40-60% of healthy individualswithout any history of autoimmune disease. In addition,
Souwer and colleagues [72] show that elastase is required
for the generation of Th17 responses, owing to its cleavage
of DC-produced CXCL8 into a more potent form. How this
paper ﬁts into the literature on elastase is complicated; it is
in agreement with the proinﬂammatory nature of NETs,
which contain elastase (see Section 4.2 'NETosis') but not
with the previous research using elastase in isolation. This
incongruence may be a result of the populations of T cells
being used in this paper being highly pure, something that
is often not the case with older studies.
4.1.4. Cathelicidin LL-37. The cathelicidin LL-37 is a 4 kDa
cationic amphipathic peptide stored in secondary granules
as the inactive precursor hCAP-18 before being cleaved by
proteinase 3 during degranulation. Although it has long
been known as a powerful antimicrobial, antifungal, and
antiviral agent, now we also recognise its profound immu-
nomodulatory roles.
Cathelicidin is one of the granule peptides most investi-
gated for its role in adaptive immunity, with many inﬂuences
on DC and T cells described. Interestingly, and reﬂecting
data seen with MPO and elastase, results are split between
pro- and anti-inﬂammatory outcomes (see Table 1), suggest-
ing either concentration-dependent eﬀects or that it acts in
concert with other local mediators to produce dichotomous
results. During inﬂammatory disease, LL-37-speciﬁc T cells
exist; up to 75% of patients with severe psoriasis have T cells
recognising LL-37, and these T cells are pathogenic and pro-
duce proinﬂammatory cytokines [73]. T cells from patients
with psoriasis proliferate and produce IFN-γ in response to
ex vivo LL-37 exposure, while T cells from healthy control
donors do not. Interestingly, LL-37-speciﬁc T cells were seen
6 Mediators of Inﬂammationmore frequently in patients with severe disease than with
mild clinical scores. A diﬀerent study [74] showed increased
proliferation in healthy control CD4+ T cells with LL-37
exposure—this occurred in the presence and absence of DCs.
Similarly, delivery of murine cathelicidin (mCRAMP) to
ApoE-/- mice induced activated degranulating CD8+ T cells
with increased proliferation and IFN-γ production [75].
CD4+Tcellsmigrate towardsLL-37 [76, 77]andwholeperiph-
eral blood leukocytes towardsmurine cathelin-related antimi-
crobial peptide (CRAMP) [78] in a dose-dependent fashion,
but interestingly CD8+ T cells do not [77].
LL-37 can bind DCs directly (a review of the peptide’s
receptors is included in [79]), inducing maturation and
CD86 expression on DCs [80]; this subsequently primes Th1
responses and induces the production of IFN-γ. This occurs
via binding to the G protein-coupled receptor FPR2 [81].
A prominent role of LL-37 is to form complexes with
self-DNA and allow its take up by plasmacytoid DC (pDC).
LL-37-DNA complexes move into the endocytic pathway of
the DC and therefore promote a strong IFN-α response
[82]; this pDC type 1 interferon production then matures
cDC and leads to pathogenic proliferation and activation of
Th1 cells [83]. The same phenomenon—LL-37-facilitated
priming of pDC—is seen with bacterial DNA and CpG,
allowing rapid responses to microbes [84]. Coexposure to
LL-37 and CpG DNA induced the expression of costimula-
tory molecules CD86 and CD40 and production of IL-6
within ﬁve-minute exposure; this was speciﬁc, as T cells did
not respond to CpG-LL-37 complexes.
In vivo, injection of CRAMP alongside OVA led to an
enhancement of immune responses—proliferation of spleno-
cytes, IL-4, IL-6, IL-10, and IFN-γ production—without
skewing of responses [78]. Finally, the proinﬂammatory role
of LL-37 has been targeted in cancer therapy. In a model of
mice challenged with SP2/0-CSFRj6-1 tumour cells, LL-37
enhanced vaccination with a DNA vaccine against
M-CSFRj6-1. Addition of LL-37 to the vaccine improved
the cytotoxic T cell response, IFN-γ, and IL-4 production
and resulted in prolonged survival [85]. In summary, there-
fore, there are a number of profoundly proinﬂammatory out-
comes following LL-37’s interaction with DC and T cells.
One intriguing study shows that LL-37 is not uniformly
proinﬂammatory but is more discriminating in its immuno-
modulation. Nijnik et al. [86] showed that LL-37 inhibited
IFN-γ-induced priming of DC, monocytes, and macro-
phages, abolishing TNF production following IFN-γ expo-
sure. In combination with IFN-γ, LL-37 suppressed TNF
production following LTA stimulation but not that resulting
from Pam3Csk4, ﬂagellin, or NOD2.
Similarly, an increasing body of literature shows LL-37
can also be selectively anti-inﬂammatory. It speciﬁcally
inhibits TLR4 ligand signalling in DCs, with no eﬀect on
TLR2 signalling [87]. This, in the context of a murine model
of allergic contact dermatitis, means that LL-37 has an
anti-inﬂammatory role. In this paper, LL-37 prevented the
DC production of IL-6, IL-8, IL-10, and TNF following LPS
treatment, but not IL-1β or GMCSF; this was via prevention
of aggregation of the membrane receptor complex required
for signal transduction.Human DC react similarly to mouse; LL-37 inhibits
monocyte-derived DC priming by LPS and subsequent
stimulation of T cell proliferation [88]. IL-6 and TNF were
totally inhibited by a physiologically relevant dose of LL-37.
However, in this study, the signalling by TLR2 and TLR5
ligands (LTA and ﬂagellin) was also inhibited by LL-37.
Direct eﬀects on murine T cells show that it may induce
apoptosis of certain cells [89, 90], in particular T regulatory
cells and cytotoxic CD8+ T cells, which are signiﬁcantly more
sensitive to LL-37 than CD4+ cells. However, doses of LL-37
used in these studies were high (up to 100μg/ml). Murine
cathelicidin (mCRAMP) also prevents the development of
Th2 responses in vitro; isolated T cells from mice lacking
cathelicidin overexpress Th2 in vitro while Th1 responses
are normal [91].
4.1.5. Lactoferrin. Lactoferrin is an 80 kDa protein from the
transferrin family present alongside LL-37 in the secondary
granules of neutrophils; it is abundant in milk and has strong
antimicrobial activity.
When immature human DCs are incubated with lactofer-
rin, it induces an increase in maturation (CD83), activation
(CD80, CD86), proinﬂammatory cytokine production (with
discrepancies between reports), and CCR7 expression
(resulting in migration towards CCL21) [92–94]. Conse-
quently, T regulatory cell development is decreased and
Th1 cells enhanced. These eﬀects on DC required TLR2
and TLR4 signalling [93].
Used as an adjuvant during sheep red blood cell induced
delayed type hypersensitivity, lactoferrin enhances inﬂam-
mation and increases TNF, IL-10, and MIP1α production
by total peritoneal cells [95], with subsequent increased
lymphocyte proliferation. This is however using a very high
dose (>50μg/ml).
Interest in using bovine lactoferrin as an adjuvant led to
its use alongside Mycobacterium bovis Calmette-Guerin
(BCG). BCG-infected DCs which had been exposed to lacto-
ferrin showed an increase in activation and costimulation
markers and increased stimulation of Th1 cells [96]. Use in
this system led to a substantial increase in CD4+ splenic T
cells producing IFN-γ [97] compared to BCG alone,
ultimately leading to a reduction in Mycobacterium tubercu-
losis-induced pathology [98].
Coculture of neutrophils and CD4+ T cells results in the
transfer of lactoferrin to the T cell surface [99]. Using the
Jurkat cell line, lactoferrin was shown to induce tyrosine
phosphorylation in the T cells 10 minutes after exposure; this
upregulated CD4 expression through MAPK signalling, and
potentially therefore CD3 complex signalling capability
[100]. In mice expressing functional human lactoferrin, this
boost to T cell signalling resulted in increased TNF and IFN-γ
production and improved bacterial clearance during Staphy-
lococcus aureus infection [101]. Lactoferrin also has been
shown to have positive impacts on T cell diﬀerentiation and
maturation; it promotes CD4 expression and maturation of
CD4+ cells from precursors and enhances proliferation
[102, 103]. Oral administration of bovine lactoferrin boosts
CD4+ and CD8+ T cell numbers in the intestine [104].Admin-
istration of lactoferrin following cyclophosphamide-mediated
7Mediators of Inﬂammationdepletion restores T cell populations inmice [105]. Peripheral
blood and splenic lymphocyte populations were signiﬁcantly
restored, particularly CD4+ T cells [105]. These interesting
results, in toto, suggest that lactoferrin could be used to boost
CD4+ T cells in immunosuppressed individuals.
A truncated lactoferrin peptide comprising the ﬁrst 11
residues from the N-terminus, hLF1-11, is of interest as a
novel antimicrobial. Exposure of diﬀerentiating DC to
hLF1-11 increases their maturation and their ability to
phagocytose Candida albicans and subsequently produce
more IL-6 and less IL-12p40 [106]. This led to increased gen-
eration of Th17 cells.
Lactoferrin applied to pig small intestine mucosal
explants [107] is rapidly taken up by lamina propria T cells,
and administration of oral recombinant human lactoferrin
results in the activation and proliferation of intestinal T cells
[108], particularly CD8+ T cells which showed enhanced
IFN-γ production and improved responses to implanted
tumours. However, lactoferrin has well-known anti-
inﬂammatory role in mouse and rat models of colitis [109,
110], and this appears to be a result of it decreasing Th1
and Th17 cells in the mesenteric lymph nodes and intestinal
lamina propria and skewing towards T regulatory cells
instead [111]. This may be a consequence of lactoferrin
binding pathogen-associated molecular patterns (PAMPs)
such as LPS and therefore dampening down immunity in
the gut rather than directly acting on the T cells. However,
the possibility remains that in the generally immunosuppres-
sive environment of the intestinal mucosa, the signals gener-
ated in T cells by lactoferrin result in T regulatory cell
development and suppression of immunopathology. The
route of supply of lactoferrin also may have an impact, with
single buccal dose and continual diet dosing increasing Th2
responses in the gut, while gastric intubation for delivery
increased Th1 cytokine production [112].
Some other work has shown an inhibitory role of
lactoferrin on T cell responses. It inhibits proliferation of
T cells in an MLR [113] and inhibited proliferation and
cytokine production of a Th1 cell line (but not Th2)
[114]. Likewise, the transfer of lactoferrin to CD4+ T cells
[99] induces suppression of IFN-γ and enhancement of
IL-10 in the activated T cells, suggesting this is another
possible route of neutrophil-induced T cell regulation.4.1.6. Arginase-1. Arginase-1 is present in the tertiary
(gelatinase) granules; however, it is inactive at physiological
pH unless activated by factors released by primary granule
release [115]. Once released, it converts arginine to
L-ornithine; as arginine is required for the expression of
the T cell receptor zeta chain and subsequent proliferation
of T cells [116, 117], the depletion of arginine results in cell
cycle arrest and suppression of T cell responses; this is also
mediated via an inability to upregulate cyclin D3 [118]. In
addition, arginine is necessary for the dephosphorylation of
coﬁlin, which stabilises the immunological synapse which
forms between T cells and DC; arginase therefore destabi-
lises the synapse and prevents adequate T cell activation
[119, 120].Arginase release from neutrophils is uniformly suppres-
sive to T cell responses, unlike the more nuanced results for
other granule mediators.
In addition to infection and sites of purulent inﬂamma-
tion [117], this suppression of T cell responses via arginase
release occurs during pregnancy; neonatal neutrophils have
higher arginase content and are more suppressive than adult
neutrophils [121]. This is an intriguing explanation proposed
for why newborns are susceptible to infection. Activated
neutrophils are also present in the spleen of poststroke mice
[122], and these produce arginase, resulting in suppressed T
cells as a consequence of decreased CD3 zeta; similarly, neu-
trophils from airway neutrophils isolated from patients with
Cystic Fibrosis suppress T cell activation via arginase [123].
Myeloid-derived suppressor cells produce arginase,
which is one of the most prominent explanations for their
suppressive activity; however, much of the research described
above did not unpick relative contributions of MDSC and
suppressive neutrophil activities or which subsets of neutro-
phils were involved (see Section 5 - a note on immature
and low-density neutrophils).4.1.7. Gelatinase. Gelatinase, a 94 kDa type IV collagenase
[124], is present in the tertiary granules of neutrophils.
Research into the eﬀects of gelatinase on T cell responses
has not been examined in detail. However, recently, it has
been shown that gelatinase released from neutrophils is
indispensable for the generation of contact hypersensitivity
responses [125]. In this interesting paper, neutrophil deple-
tion reduced DC migration into the site of sensitization
(the ear) and subsequent allergen-speciﬁc T cell priming
and Th1 development. This is intriguing as gelatinase and
arginase are released from the same granules but appear to
have opposite impacts on adaptive immunity.4.1.8. Cathepsin G. Cathepsin G is a member of the serine
protease family and is predominantly found in primary neu-
trophil granules, although it has also been detected in various
myeloid cells and APCs [126, 127].
Cathepsin G can serve as a signal that ampliﬁes the
inﬂammatory response. For example, it can act as a chemoat-
tractant for neutrophils and monocytes [128]. Wittamer et al.
revealed a role for cathepsin G in the processing and matura-
tion of chemerin, a chemoattractant that speciﬁcally attracts
APCs [129]. In addition, it is responsible for the quantum
proteolytic processing of CXCL5 and CCL15 in to more
potent chemotactic factors [130].
Cathepsin G is capable of binding to human lymphocytes
and acting as a chemokinetic stimulant of T cells [128, 131].
The administration of cathepsin G in mice, together with
antigen, enhances the antibody response and increases IFNγ
and IL-4 production [132]. Furthermore, cathepsin G plays a
critical role in proinsulin processing and the activation of
diabetogenic T cells [133]. The downregulation of cathepsin
G by speciﬁc inhibitors or siRNA was shown to mitigate
the activation of CD4+ T cells in nonobese diabetic (NOD)
mice, leading to reduced blood glucose and improved
function of islet β cells [134].
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regulation of excessive inﬂammation. For instance, it can
cleave the IL-1-related alarmins IL-18 and IL-33, as well as
IL-15, which is important for both T cell and NK cell homeo-
stasis [135]. In addition, cathepsin G has been shown to
disrupt CCL5 and CCL3 chemokine gradients, both of which
recruit T lymphocytes [136, 137]. It also reduces the bioactiv-
ity of the T cell-stimulating cytokines IL-2 and IL-6 at sites of
inﬂammation and catalyzes the shedding of their receptors,
thereby enhancing its suppressive eﬀects [138].
In Cystic Fibrosis patients, cathepsin G can cleave the
surface antigens CD2, CD4, and CD8, resulting in a
temporary functional impairment of T lymphocytes and
a state of immunological unresponsiveness in inﬂamma-
tory foci [139]. Kish et al. also recently showed that during
hapten skin sensitization, neutrophil cathepsin G inhibits
the production of IL-12 from hapten-presenting DCs. This
in turn suppresses the development of hapten-reactive
CD4+ T cells and their diﬀerentiation in to IFNγ-produ-
cing eﬀector cells [140].4.1.9. Cathepsin D. Cathepsin D is an aspartyl protease,
ubiquitously distributed in lysosomes. It has been impli-
cated in a wide variety of biological processes, including
proteolytic degradation and apoptosis, as well as various
inﬂammatory disorders.
Cathepsin D has been suggested to play an essential
role in tissue homeostasis. For example, it is required for
the survival of mice beyond 4 weeks [141]. Mice deﬁcient
for this enzyme exhibited progressive atrophy of the intes-
tinal mucosa and profound destruction of the lymphoid
organs and cells [141]. Moreover, ceramide activates lyso-
somal cathepsin D (and B) to attenuate autophagy and
induce ER stress to suppress myeloid-derived suppressor
cells [142].
Cathepsin D is also involved in class II MHC-restricted
antigen processing and the generation of T cell epitopes. This
wasﬁrst shown in 1994whenM. vanNoort demonstrated that
cathepsinDcould induce the release of T cell stimulatory frag-
ments from hen egg white lysozyme (HEL) in vitro. Cathepsin
D has since been implicated in the proteolytic processing of
thyroglobulin, myoglobulin, and tetanus toxin [143–145].
While not in neutrophils, DC cathepsin D is required for lipid
antigen presentation by DCs: ligand activation of PPARg
(Peroxisome Proliferator-Activated Receptor g) upregulates
cathepsinD, which in turn generates themature formof sapo-
sins, lipid transfer molecules that facilitate lipid loading to
CD1dmolecules [146].
On the other hand, cathepsin D has also been implicated
in apoptosis and the resolution of innate immune responses.
Caspase 8 is directly activated by cathepsin D, which in turn
triggers a proapoptotic pathway in neutrophils. Inactivation
of cathepsin D by both genetic and pharmacological means
delayed neutrophil apoptosis and prolonged the inﬂamma-
tory response to LPS in vivo [147]. Bidere et al. also demon-
strated that cathepsin D triggers a rapid conformational
change in Bax upon apoptotic signalling. This induces the
release of mitochondrial apoptosis-inducing factor (AIF),which controls the early apoptotic phenotype in activated
T lymphocytes [148].
4.2. NETosis. Neutrophils release extracellular ﬁbres known
as neutrophil extracellular traps (NETs, [7]). NETs comprise
cytoplasmic and granule proteins bound to a web of chroma-
tin, and their expulsion encapsulates and kills microbes.
Notably, murine neutrophils produce NETs more slowly
and less eﬃciently than human neutrophils; however, these
diﬀerences could be attributed to murine neutrophils being
isolated from the bone marrow, while human neutrophils
are peripherally derived [149].
NETosis can be triggered by a wide range of stimuli
including, in vitro, biochemical agents, pathogens (for exam-
ple, Staphylococcus aureus), and their products (for example,
LPS), although PMA (phorbol 12-myristate 13-acetate) is
used most often as it potently induces NETting in all studies
[150–152].
Neutrophil products, including granule contents, embed-
ded within NETs can cause host tissue damage and disease
[153]. The ﬁrst study to describe NETs analysed their compo-
sition using immunoﬂuorescence and noted DNA, histones,
neutrophil elastase (NE), cathepsin G, myeloperoxidase
(MPO), lactoferrin, and gelatinase [7]. This suggested a
network of DNA decorated with many granule proteins. A
more recent proteomic approach analysing PMA-induced
NETs identiﬁed 24 NET-associated proteins, including
granule proteins in addition to cytoplasmic proteins such as
calprotectin, and cytoskeletal proteins actin β/γ [154]; the
most abundant nonhistone protein was NE. Of importance
for interpretation, the proteomic analysis did not ﬁnd previ-
ously describedNET-associatedproteinsH1, BPI, cathelicidin
(hCAP-18), and pentraxin 3 (PTX-3). Subsequent immuno-
blot analysis established the presence of BPI, but not of
PTX-3 or hCAP-18. They propose that these proteins perhaps
are loosely attached toNETs and thereforewere lost during the
isolation procedure [154]. It has also been suggested that
diﬀerent stimulants can induce varying NET composition.
Many NET experiments are performed following induc-
tion of NETosis with PMA, which also profoundly activates
T cells. Although attempts are made to wash NETs and
control for this, it must be borne in mind when interpreting
the impact of NETs on adaptive immunity. New methods
of inducing NETs without PMA [151] are now deﬁned, and
use of these will allow conﬁrmation of current results.
The presence of antimicrobial peptides in the NET
structure licences the DNA to become immunomodulatory
and to activate DCs. NETs stably interact with DCs, unlike
apoptotic or live neutrophils [155], and the DCs take up
NET components, notably proteinase 3 andmyeloperoxidase.
NETs induce type one interferon production by pDCs, a ﬁrst
step to autoimmunity [156], and promote Th1 responses in
the mouse model collagen-induced arthritis [157] through
enhancing DCmaturation and costimulation. In the rheuma-
toid joint, NETs containing citrullinated peptides are taken
up by ﬁbroblasts, which then present NET peptides to local
T cells [158]; this leads to damage of local cartilage and devel-
opment of autoimmune populations of T cells. NET
fragments (following digestion with DNAse) induce CD40,
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marrow-derived DCs via TLR-MyD88 signalling [159]; this
led to proliferation of allogeneic CD4+ T cells. This is impor-
tant as DNAse is suggested as a therapy for many diseases and
is approved for use in Cystic Fibrosis. NETs are triggered by
cigarette smoke, and these drive pDC maturation and activa-
tion [160]. NETs and cigarette smoke extract together
induced pDC to upregulate CD40, CD86, and MHC II and
to produce IFN-α, IL-6, and IL-12p70. As a result, these pDCs
produced more inﬂammatory cytokines (IFN-γ and IL-17),
consequent to increased Tbet and RORγt, than pDC exposed
to air control. This is proposed to be one way in which inﬂam-
matory responses are generated and maintained in COPD.
NETs are released by patients with SLE complex self
DNA and the granule peptides LL-37 and HNPs; these
NET-DNA complexes triggered TLR9 and promoted patho-
genic type 1 IFN release [161].
In addition to priming DCs, NETs can act directly on
CD4+ T cells. Human T cells reacted to NETs by increased
phosphorylation of the tyrosine kinase ZAP70, which is
critical for downstream T cell activation [162]. This led to
increased expression of the activation markers CD25 and
CD69. Mechanistically, it appears that the presence of NETs
primes CD4+ T cells so that they are able to respond to and
proliferate following the presentation of low doses of antigen,
even in the absence of costimulation. NETs—and neutrophils
in general—are most frequently associated with Th17
responses in local T cells, but they can also induce Th2
responses. Recently it has been shown that NETs induced
in the lung following rhinovirus infection promote type 2
immunity and exacerbations of asthma [163].
HIV or SIV-infected individuals overproduce NETs. It is
suggested that these NETs trap and induce apoptosis in
CD4+ and CD8+ T cells and that this may be one mechanism
by which these T cells are lost during infection [164].
In summary, NETs are highly proinﬂammatory for DC
and T cell responses, and the granule peptides coating these
NET strands play a large part in this, despite their frequent
anti-inﬂammatory roles when used in isolation. It is possi-
ble that increased concentration on the strands licences
proinﬂammatory roles, that the particular combination of
proteins acts in concert with unexpected outcomes for T
cells, or that the presence of DNA tips the balance from
anti- to proinﬂammatory.
Intriguingly, a regulatory role for NETs is shown in [165].
This paper exposed monocyte-derived DC to human NETs
andshowedhowthisdownregulatedLPS-inducedmaturation,
cytokine production, and costimulatory molecule expression.
Unsurprisingly, this had the consequence of reducing subse-
quent CD4+ T cell proliferation [165]. In this paper, NET
fragmentswere induced and isolatedwithA23187 stimulation
then Alu1 restriction enzyme treatment. It is possible that
diﬀerences in outcome from published NET papers reﬂect the
methods of isolation.
Finally, it is worth noting that not only NETs released by
neutrophils impact the adaptive immune response; the cell
bodies, cytoplasts, left behind following NETosis are also
capable of doing so. In asthma, it has been shown that these
cytoplasts were present in draining lymph nodes and inducedDC to promote Th17 generation [166]. This exciting paper
opens up a whole new area of research as we consider how
neutrophils can aﬀect T cells in lymph nodes.
5. A Note on Immature and Low-Density
Neutrophils and Myeloid-Derived
Suppressor Cells
Isolation of neutrophils using density gradients can allow
some neutrophils to come out in the isolated PBMC layer;
these low-density neutrophils impair T cell proliferation
in vitro andmay represent granulocytic myeloid-derived sup-
pressor cells (MDSC), although the low-density layer may
also include more than one population [167, 168]. It is not
currently possible to fully distinguish myeloid-derived sup-
pressor cells from mature neutrophils [32], both being
CD14- CD15+ CD11b+ CD66b+ HLADR- [32]. Further-
more, many of the studies in this review were performed
before the era of MDSC, and as such it is not possible to
unpick relative impacts of MDSC vs. activatory neutrophils
in each case.
Recently, CD10 has been identiﬁed as amarker which dis-
criminates between mature (CD10+) and immature (CD10-)
neutrophils, with the former inhibiting T cells via arginase-1
and the latter promoting T cell proliferation and IFN-γ pro-
duction [168]. Increasing the use of thismarker inﬂowcytom-
etry panels may enable discrimination of these subsets and
examination of their impact during inﬂammatory disease. It
remains an intriguing possibility that the dichotomous results
presented at the beginning of this article, from in vitro and
in vivo experiments over many decades, may include results
from soon-to-be clearly delineated subsets of cells—and that
we may soon be able to examine them with fresh eyes.
Overall, what this means is that it is essential for
researchers to examine and present neutrophil maturation
status and gross phenotype clearly, as well as clearly describ-
ing isolation methods used, so that readers are in full knowl-
edge of the facts.
Finally, neutrophils can interact with Dynabead-style
activation beads which are commonly used to activate T cells
[167], leading to suppression of T cell proliferation in vitro
which does not reﬂect in vivo situations. This must be consid-
ered when reﬂecting on published data.
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